Provider review · Checked September 27, 2026
Noom semaglutide microdosing review: program identity, price changes and reported outcomes
Examine Noom’s current Microdose offer without mixing its medicines, introductory pricing, renewal terms or customer-data populations.
Public-document editorial research · Method and limitations
Noom's Microdose offer is a program bundle rather than a medicine name alone. Its pages describe clinical care, behavioral support and medication when prescribed. That broader package changes the questions a review needs to ask: which medicine is included, what period does each charge cover, and what evidence supports the result being advertised? A recognizable brand does not make those details interchangeable.
Sema Evidence has a promotional relationship with CoreAge Rx, whose first commercial placement is disclosed throughout this publication. This competitor review does not claim independent clinical ranking or personal experience. We examined Noom's official records on September 27, 2026; no questionnaire, prescription, payment, coaching session or cancellation was completed.
Article contents
The Microdose name now includes more than semaglutide
The current Microdose page explicitly lists compounded semaglutide and tirzepatide offerings. It describes medication if prescribed, clinical access and behavioral coaching. Those ingredients and products are distinct, so a semaglutide review cannot attribute every result or price across the entire GLP-1 catalog to one exact preparation.
The page also states that access is not available in all states and that medication depends on clinical appropriateness. Neither a published offer nor this review determines eligibility. Our microdosing terminology guide explains why a program label does not define a universally accepted protocol, indication or safety standard.
The introductory price and renewal cover different periods
The Microdose page advertises a $79 starting offer. Its footnote distinguishes an initial three-week subscription from four weeks of medication, with $179 per month plus tax for a subsequent twelve-week subscription; final pricing depends on the selected program. The September 22 cost article describes the later charge as $537 every twelve weeks. That is more informative than treating the introduction as a recurring monthly price.
The pricing directory also displays $49 alongside $79 for starting Microdose care. We did not resolve a personal promotion or checkout total. The exact introductory amount, covered period and renewal authorization need to be read together, not selected from whichever page appears cheapest.
Dated articles are not automatically the current offer
A microdosing article updated September 3 still describes a $199 monthly continuation and a differently dated pricing qualification. The current program page instead displays $179 continuation language and a July 27 new-account effective date. These are source-specific differences, not evidence that an enrolled patient has been charged incorrectly.
This review therefore does not present either a dated article or the lowest visible promotional card as a guaranteed invoice. Noom's pricing page distinguishes bundled compounded-medication programs from branded-medication telehealth where the medicine cost is separate. A price from that different service must not be added to or substituted for this bundle without an actual plan record.
An up-to result is not the average result
The pricing directory qualifies its seventeen-pound, sixty-day headline as the top quarter of self-reported outcomes among 1,185 Noom Med users prescribed compounded GLP-1s. The same footnote gives an average of thirteen pounds. Its population description is broader than verified recipients of one exact semaglutide microdose formulation; it is not a randomized comparison against another provider.
The dedicated Microdose page also contains a separate footnote concerning 3,562 users and a different average. Those denominators should not be merged into one study. Our study-population guide explains how selection, follow-up and the endpoint change what a reported figure can support.
The bundle makes attribution especially important
Noom includes coaching, digital tools and clinical support alongside medication. A reported change during such a program cannot automatically identify the separate effect of the medicine, app engagement or other behavior changes. The pricing directory itself qualifies an engagement-related weight-loss comparison as an association that does not establish causation.
That caution also applies to testimonials. They can describe a person's reported experience without establishing what another person will achieve. The longevity claims guide addresses a further leap: neither a weight-change report nor a broader wellness description demonstrates longer life from microdosing. We found no basis in these offer records for converting either into that conclusion.
Compounded and lower dose do not establish approved safety
Noom discloses that its compounded products have not received FDA review for safety, efficacy or quality. Describing production in an FDA-registered facility does not mean the finished drug is FDA-approved. FDA's current GLP-1 concerns address dosing errors, product identity and other risks; this review does not determine legal compliance or quality for an unexamined individual prescription.
The June 2026 Wegovy label remains an approved-product reference with defined populations and significant precautions. Its evidence cannot be transferred intact to Noom's compound. Lower-dose marketing is not a reason to bypass professional assessment of other medicines, medical history, symptoms or follow-up responsibilities.
The useful conclusion is specific, not a brand verdict
Noom has a current explicit microdosing offer, a defined support bundle and accessible pricing qualifications. Its multiple medicines, introductory offers, dated articles and self-reported outcome populations still need to be distinguished. None of those findings permits this publication to predict individual weight loss, promise fewer adverse effects or recommend a personal treatment schedule.
Use the care-offer comparison to compare those categories with other records. Our CoreAge review applies the same evidence boundaries despite the commercial relationship. The next meaningful document is the exact medicine and care agreement, not a generalized assumption that every plan under the brand has the same terms.
Source documents
A provider record supports a statement about its public description. Trial reports and product labels answer different questions and retain their own population, formulation and outcome limits.
- Noom: Microdose GLP-1Rx program and offer qualificationsProvider program description · Checked 2026-09-27
- Noom: program cost article, updated September 22, 2026Provider cost explanation · Checked 2026-09-27
- Noom: current medication programs and pricingProvider pricing and outcome footnotes · Checked 2026-09-27
- Noom: microdosing GLP-1 article, updated September 3, 2026Provider educational marketing and older price terms · Checked 2026-09-27
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight LossCurrent regulatory safety information · Checked 2026-09-27
- Wegovy prescribing information, revised June 2026Approved-product prescribing information · Checked 2026-09-27